3,470 reports of this reaction
2.4% of all MESALAMINE reports
#8 most reported adverse reaction
HAEMATOCHEZIA is the #8 most commonly reported adverse reaction for MESALAMINE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 3,470 FDA adverse event reports linking MESALAMINE to HAEMATOCHEZIA. This represents approximately 2.4% of all 145,688 adverse event reports for this drug.
Patients taking MESALAMINE who experience haematochezia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATOCHEZIA is a less commonly reported adverse event for MESALAMINE, but still significant enough to appear in the safety profile.
In addition to haematochezia, the following adverse reactions have been reported for MESALAMINE:
The following drugs have also been linked to haematochezia in FDA adverse event reports:
HAEMATOCHEZIA has been reported as an adverse event in 3,470 FDA reports for MESALAMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATOCHEZIA accounts for approximately 2.4% of all adverse event reports for MESALAMINE, making it a notable side effect.
If you experience haematochezia while taking MESALAMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.